Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism

BACKGROUND: Sclerostin is a paracrine acting factor, which is expressed in the osteocytes and articular chondrocytes. Sclerostin decreases the osteoblast-related bone formation through the inhibition of the Wnt/β-catenin pathway. Osteocytes also express the Calcium sensing receptor which is a target...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuczera, Piotr, Adamczak, Marcin, Więcek, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111350/
https://www.ncbi.nlm.nih.gov/pubmed/27846800
http://dx.doi.org/10.1186/s12882-016-0392-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111350/
https://www.ncbi.nlm.nih.gov/pubmed/27846800
http://dx.doi.org/10.1186/s12882-016-0392-6

Ejemplares similares